Research programme: factor Xa inhibitors - Millennium
Latest Information Update: 21 Jun 2001
At a glance
- Originator Millennium Pharmaceuticals
- Class Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atrial fibrillation; Thrombosis
Most Recent Events
- 21 Jun 2001 Discontinued-Preclinical for Atrial fibrillation in USA (Unknown route)
- 21 Jun 2001 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
- 20 Jul 2000 Preclinical development for Atrial fibrillation in USA (Unknown route)